Addus Homecare (A41) Stock Forecast & Price Target

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

A41 Analyst Ratings

Moderate Buy

6 Buy

2 Hold

1 Sell

Based on 9 analysts giving stock ratings to

Addus

Homecare

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

A41 Stock 12 Month Forecast

Average Price Target

€109.94

▲(8.86% Upside)

Based on 9 Wall Street analysts offering 12 month price targets for Addus Homecare in the last 3 months. The average price target is €109.94 with a high forecast of €126.52 and a low forecast of €83.77. The average price target represents a 8.86% change from the last price of €101.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"76":"€76","127":"€127","88.75":"€88.8","101.5":"€101.5","114.25":"€114.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":126.52263405,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€126.52</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":109.94380613999999,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€109.94</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":83.76670944,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€83.77</span>\n  </div></div>","useHTML":true}}],"tickPositions":[76,88.75,101.5,114.25,127],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97,99.27097185,101.5419437,103.81291555,106.0838874,108.35485925,110.6258311,112.89680295,115.16777479999999,117.43874665,119.7097185,121.98069035,124.2516622,{"y":126.52263405,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97,97.99567739538462,98.99135479076924,99.98703218615384,100.98270958153846,101.97838697692308,102.9740643723077,103.9697417676923,104.96541916307692,105.96109655846153,106.95677395384615,107.95245134923076,108.94812874461537,{"y":109.94380613999999,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,97,95.98205457230769,94.96410914461538,93.94616371692308,92.92821828923077,91.91027286153846,90.89232743384615,89.87438200615385,88.85643657846154,87.83849115076923,86.82054572307692,85.80260029538462,84.78465486769231,{"y":83.76670944,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":96.5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":98.5,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":104,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":101,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":92,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.5,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.5,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.5,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.5,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":100,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":97,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€126.52

Average Price Target€109.94

Lowest Price Target€83.77

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Clarke Murphy

Truist Financial

―

Buy

―

Reiterated

09/15/26

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Addus Homecare (NASDAQ: ADUS) and Perspective Therapeutics (NYSE MKT: CATX)

Jared Haase

William Blair

―

Buy

―

Reiterated

09/14/26

Analysts Offer Insights on Healthcare Companies: Addus Homecare (NASDAQ: ADUS) and Cardiff Oncology (NASDAQ: CRDF)

Joanna Gajuk

Bank of America Securities

€109.07

Hold

7.99%

Upside

Downgraded

09/14/26

Addus HomeCare downgraded to Neutral from Buy at BofAAddus HomeCare downgraded to Neutral from Buy at BofA

Sean Dodge

BMO Capital

€100.35

Hold

-0.65%

Downside

Reiterated

09/02/26

Addus Hold Rating Reiterated as Growth Prospects Offset by Medicaid Uncertainty; $115 Price Target Unchanged

Andrew Mok CFA

Barclays

€83.77

Sell

-17.06%

Downside

Reiterated

08/28/26

Barclays Reaffirms Their Sell Rating on Addus Homecare (ADUS)

Ben Hendrix

RBC Capital

€113.43→€116.92

Buy

15.77%

Upside

Reiterated

08/05/26

Addus HomeCare price target raised to $134 from $130 at RBC CapitalAddus HomeCare price target raised to $134 from $130 at RBC Capital

Raj Kumar CFA

Stephens

€118.67

Buy

17.49%

Upside

Reiterated

08/05/26

Addus Homecare (ADUS) Receives a Buy from Stephens

Ryan Langston

TD Cowen

€114.31

Buy

13.17%

Upside

Assigned

08/04/26

Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Addus Homecare (NASDAQ: ADUS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

A.J. Rice

UBS

€126.52

Buy

25.27%

Upside

Reiterated

06/24/26

Addus Homecare: Buy Rating Reiterated on Steady Volume Momentum, Acquisition Outperformance, and Double-Digit Growth Ambitions

Matthew Gillmor CFA

KeyBanc

―

Buy

―

Reiterated

05/07/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Michael Wiederhorn

Oppenheimer

€135.25

Buy

33.91%

Upside

Assigned

05/06/26

Oppenheimer Sticks to Their Buy Rating for Addus Homecare (ADUS)

John Ransom

Raymond James

―

Buy

―

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX), Compass Therapeutics (NASDAQ: CMPX) and Addus Homecare (NASDAQ: ADUS)

Constantine Davides

Citizens JMP

€130.89→€123.9

Buy

22.68%

Upside

Reiterated

05/06/26

Addus HomeCare price target lowered to $142 from $150 at CitizensAddus HomeCare price target lowered to $142 from $150 at Citizens

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Clarke Murphy

Truist Financial

―

Buy

―

Reiterated

09/15/26

Analysts Conflicted on These Healthcare Names: Sarepta Therapeutics (NASDAQ: SRPT), Addus Homecare (NASDAQ: ADUS) and Perspective Therapeutics (NYSE MKT: CATX)

Jared Haase

William Blair

―

Buy

―

Reiterated

09/14/26

Analysts Offer Insights on Healthcare Companies: Addus Homecare (NASDAQ: ADUS) and Cardiff Oncology (NASDAQ: CRDF)

Joanna Gajuk

Bank of America Securities

€109.07

Hold

7.99%

Upside

Downgraded

09/14/26

Addus HomeCare downgraded to Neutral from Buy at BofAAddus HomeCare downgraded to Neutral from Buy at BofA

Sean Dodge

BMO Capital

€100.35

Hold

-0.65%

Downside

Reiterated

09/02/26

Addus Hold Rating Reiterated as Growth Prospects Offset by Medicaid Uncertainty; $115 Price Target Unchanged

Andrew Mok CFA

Barclays

€83.77

Sell

-17.06%

Downside

Reiterated

08/28/26

Barclays Reaffirms Their Sell Rating on Addus Homecare (ADUS)

Ben Hendrix

RBC Capital

€113.43→€116.92

Buy

15.77%

Upside

Reiterated

08/05/26

Addus HomeCare price target raised to $134 from $130 at RBC CapitalAddus HomeCare price target raised to $134 from $130 at RBC Capital

Raj Kumar CFA

Stephens

€118.67

Buy

17.49%

Upside

Reiterated

08/05/26

Addus Homecare (ADUS) Receives a Buy from Stephens

Ryan Langston

TD Cowen

€114.31

Buy

13.17%

Upside

Assigned

08/04/26

Analysts Offer Insights on Healthcare Companies: Moleculin Biotech (NASDAQ: MBRX), Addus Homecare (NASDAQ: ADUS) and Rhythm Pharmaceuticals (NASDAQ: RYTM)

A.J. Rice

UBS

€126.52

Buy

25.27%

Upside

Reiterated

06/24/26

Addus Homecare: Buy Rating Reiterated on Steady Volume Momentum, Acquisition Outperformance, and Double-Digit Growth Ambitions

Matthew Gillmor CFA

KeyBanc

―

Buy

―

Reiterated

05/07/26

Wall Street Analysts Are Bullish on Top Healthcare Picks

Michael Wiederhorn

Oppenheimer

€135.25

Buy

33.91%

Upside

Assigned

05/06/26

Oppenheimer Sticks to Their Buy Rating for Addus Homecare (ADUS)

John Ransom

Raymond James

―

Buy

―

Reiterated

05/06/26

Analysts Offer Insights on Healthcare Companies: GoodRx Holdings (NASDAQ: GDRX), Compass Therapeutics (NASDAQ: CMPX) and Addus Homecare (NASDAQ: ADUS)

Constantine Davides

Citizens JMP

€130.89→€123.9

Buy

22.68%

Upside

Reiterated

05/06/26

Addus HomeCare price target lowered to $142 from $150 at CitizensAddus HomeCare price target lowered to $142 from $150 at Citizens

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

ARWRArrowhead Pharmaceuticals

PTGXProtagonist Therapeutics

ESTAEstablishment Labs Holdings

ZVRAZevra Therapeutics

IMUXImmunic

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Addus Homecare

3 Months

Ryan LangstonTD Cowen

Success Rate

15/21 ratings generated profit

Average Return

+6.30%

Copying Ryan Langston's trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +6.30% per trade.

1 Year

Ben HendrixRBC Capital

Success Rate

15/22 ratings generated profit

Average Return

+7.24%

Copying Ben Hendrix's trades and holding each position for 1 Year would result in 68.18% of your transactions generating a profit, with an average return of +7.24% per trade.

2 Years

John RansomRaymond James

Success Rate

11/14 ratings generated profit

Average Return

+21.71%

Copying John Ransom's trades and holding each position for 2 Years would result in 78.57% of your transactions generating a profit, with an average return of +21.71% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

A41 Analyst Recommendation Trends

Rating

May 26

Jun 26

Jul 26

Aug 26

Sep 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, A41 has received 9 Buy Ratings, 3 Hold Ratings, and 3 Sell Ratings. A41 average Analyst price target in the past 3 months is 109.94.

Each month's total comprises the sum of three months' worth of ratings.

A41 Financial Forecast

A41 Earnings Forecast

Next quarter’s earnings estimate for A41 is €1.54 with a range of €1.51 to €1.61. The previous quarter’s EPS was €1.49. A41 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year A41 has Performed in-line its overall industry.

A41 Sales Forecast

Next quarter’s sales forecast for A41 is €335.47M with a range of €333.51M to €336.92M. The previous quarter’s sales results were €325.73M. A41 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year A41 has Performed in-line its overall industry.

A41 Stock Forecast FAQ

What is DE:A41’s average 12-month price target, according to analysts?

Based on analyst ratings, Addus Homecare’s 12-month average price target is 109.94.

What is DE:A41’s upside potential, based on the analysts’ average price target?

Addus Homecare has 8.86% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Addus Homecare a Buy, Sell or Hold?

Addus Homecare has a consensus rating of Moderate Buy, which is based on 6 buy ratings, 2 hold ratings and 1 sell ratings.

What is Addus Homecare’s share price target?

The average share price target for Addus Homecare is 109.94. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €126.52 ,and the lowest forecast is €83.77. The average share price target represents 8.86% Increase from the current price of €101.

What do analysts say about Addus Homecare?

Addus Homecare’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 9 Wall Streets Analysts.

How can I buy shares of Addus Homecare?

To buy shares of DE:A41, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Addus Homecare (A41) Stock Forecast & Price Target

A41 Analyst Ratings

A41 Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Addus Homecare

A41 Analyst Recommendation Trends

A41 Financial Forecast

A41 Earnings Forecast

A41 Sales Forecast

A41 Stock Forecast FAQ

Detailed List of Analyst Forecasts